Quantinno Capital Management’s CRH CRH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.5M Buy
223,644
+31,603
+16% +$3.71M 0.04% 553
2025
Q4
$24M Buy
192,041
+70,956
+59% +$8.45M 0.05% 457
2025
Q3
$14.5M Buy
121,085
+38,007
+46% +$4.01M 0.04% 515
2025
Q2
$7.63M Buy
83,078
+10,516
+14% +$959K 0.03% 645
2025
Q1
$6.38M Buy
72,562
+25,605
+55% +$2.52M 0.04% 547
2024
Q4
$4.35M Buy
46,957
+5,152
+12% +$496K 0.04% 533
2024
Q3
$3.88M Buy
41,805
+8,071
+24% +$678K 0.05% 472
2024
Q2
$2.52M Buy
33,734
+3,860
+13% +$308K 0.05% 498
2024
Q1
$2.58M Buy
29,874
+2,900
+11% +$222K 0.06% 415
2023
Q4
$1.79M Buy
26,974
+6,451
+31% +$389K 0.06% 423
2023
Q3
$1.12M Buy
20,523
+5,127
+33% +$291K 0.05% 485
2023
Q2
$858K Sell
15,396
-332
-2% -$16.6K 0.05% 468
2023
Q1
$800K Buy
15,728
+2,781
+21% +$132K 0.05% 456
2022
Q4
$515K Buy
+12,947
New +$485K 0.04% 530

Other funds holding CRH

Quantinno Capital Management's CRH Position: Q1 2026 in Review

Quantinno Capital Management increased its CRH (CRH) stake by 16% in Q1 2026, buying an estimated $3.71M and bringing the position to 223,644 shares worth $23.5M. The position accounts for 0.04% of the portfolio, ranked #553.

Quantinno Capital Management first reported a position in CRH in Q4 2022 and has held it in 14 quarters since. The position peaked at $24M in Q4 2025. 1,006 funds tracked by Wall St. Rank hold CRH as of Q1 2026.

  • Quantinno Capital Management held 223,644 shares of CRH worth $23.5M as of Q1 2026.
  • Quantinno Capital Management bought 31,603 CRH shares in Q1 2026, an estimated $3.71M.
  • CRH made up 0.04% of Quantinno Capital Management's portfolio in Q1 2026, its #553 holding.
  • Quantinno Capital Management first reported a position in CRH in Q4 2022 and has held it in 14 quarters since.
  • Quantinno Capital Management's CRH position peaked at $24M in Q4 2025.
  • 1,006 funds tracked by Wall St. Rank held CRH as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.